ReviewThe Journal of infectious diseases2016
Extraintestinal Pathogenic Escherichia coli, a Common Human Pathogen: Challenges for Vaccine Development and Progress in the Field.
Review in The Journal of infectious diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
146 citing papers in PubMed, 1 synthesis or guideline pooled it, 244 citations in OpenAlex.
- Pooled it
- Safety, tolerability and immunogenicity of the ExPEC4V (JNJ-63871860) vaccine for prevention of invasive extraintestinal pathogenic Escherichia coli disease: A phase 1, randomized, double-blind, placebo-controlled study in healthy Japanese participants.Human vaccines & immunotherapeutics · 2018Trial
- Article
- Glycan-decorated polymeric nanomedicine for the treatment of multidrug-resistant infections.Bioactive materials · 2026Article
- Single-Cell Membrane-Permeabilization Kinetics Reveal Species-Specific Responses to Antimicrobial Photodynamic Treatment.ACS omega · 2026Article
- Article
- Extraintestinal PathogenicVeterinary sciences · 2026Article
- Machine learning-based prediction of E. coli infection in hospitalized patients using a no-code analytical framework.Scientific reports · 2026Article
- Genomic Characterization of Selected Multidrug-ResistantAnimals : an open access journal from MDPI · 2026Article
- Predictive Stability of Aggregation in Glycoconjugate Vaccines Using Advanced Kinetics Modeling and High-Throughput Screening.Pharmaceutics · 2026Article
- Global survey of extraintestinal pathogenic Escherichia coli identifies stable serogroup-virulence-resistance linkages.Genome medicine · 2026Article
- Prevalence, antibiotic resistance, and virulence gene profiles of uropathogenic Escherichia coli (UPEC) isolated from raw milk: implications for public health.Folia microbiologica · 2026Article
- Immunogenicity and Safety of the ExPEC9VVaccines · 2026Article
- Research Progress on perinatalFrontiers in microbiology · 2026Review
- Harnessing pro-inflammatory and immunopathologic immune responses in urinary tract infections for vaccine development: it's all about a balance.Frontiers in immunology · 2026Review
- De novo nucleotide biosynthesis and its dynamic regulation are crucial for systemic infection by extraintestinal Escherichia coli.PLoS pathogens · 2026Article
- The Bacterial Swiss Army Knife: ExPEC Utilizes Multiple Resistance Mechanisms to Counteract Host Immune Responses.Vaccines · 2025Review
- Microbial Surface Glycan Probe Isolates Anti-l-Rhamnose Antibodies from Human Serum for Bacterial Detection.ACS infectious diseases · 2025Article
- Article
- Dronedarone hydrochloride targets cardiolipin and phosphatidylglycerol to increase colistin susceptibility in gram-negative pathogens.Microbiology spectrum · 2025Article
86 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extraintestinal pathogenic Escherichia coli (ExPEC) is the most common gram-negative bacterial pathogen in humans. ExPEC causes the vast majority of urinary tract infections (UTIs), is a leading cause of adult bacteremia, and is the second most common cause of neonatal meningitis. Increasing multidrug resistance among ExPEC strains constitutes a major obstacle to treatment and is implicated in increasing numbers of hospitalizations and deaths and increasing healthcare costs associated with ExPEC infections. An effective vaccine against ExPEC infection is urgently needed. The O antigen, a component of the surface lipopolysaccharide, has been identified as a promising vaccine target. With the availability of a novel bioconjugation technology it is expected that multivalent O antigen conjugate vaccines can be produced at industrial scale. Clinical proof of concept of a 4-valent O antigen conjugate vaccine is ongoing. An ExPEC vaccine effective against strains that are associated with major diseases and resistant to multiple drugs could be routinely delivered to individuals at risk of developing severe E. coli infection, such as elderly people, individuals undergoing abdominal surgery and prostatic biopsy procedures, and persons at risk of recurrent and/or complicated UTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.